Simultaneous inhibition of cell-cycle, proliferation, survival, metastatic pathways and induction of apoptosis in breast cancer cells by a phytochemical super-cocktail: Genes that underpin its mode of action

Journal of Cancer

Volumn 4, Issue 9, 2014, Pages 703-715

  Ouhtit, Allal ^a,b   Gaur, Rajiv L ^a,c   Abdraboh, Mohamed ^a,d   Ireland, Shubha K ^e   Rao, Prakash N ^f   Raj, Shailaja G ^g   Al Riyami, Hamad ^b   Shanmuganathan, Somya ^b   Gupta, Ishita ^b   Murthy, Subramanyam N ^h   Hollenbach, Andrew ^a   Raj, Madhwa H G ^a,i  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SULTAN QABOOS UNIVERSITY   (Oman)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MANSOURA UNIVERSITY   (Egypt)

^e XAVIER UNIVERSITY OF LOUISIANA   (United States)

^f New Jersey Organ and Tissue Sharing Network   (United States)

^g Protegene Corporation   (United States)

^h SOUTHERN UNIVERSITY   (United States)

ⁱ Louisiana Health Sciences Center   (United States)

Author keywords

Breast cancer; Chemoprevention; Metastasis; Microarray; Phytochemicals

Indexed keywords

3 INDOLEMETHANOL; ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; CURCUMIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HERMES ANTIGEN; ISOFLAVONE; MYOSIN LIGHT CHAIN; MYOSIN REGULATED LIGHT CHAIN INTERACTING PROTEIN; PHYCOCYANIN; PROTEIN BCL 2; PROTEIN P53; QUERCETIN; RESVERATROL; RETINOBLASTOMA PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST METASTASIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CONTACT; CELL COUNT; CELL CYCLE ARREST; CELL DEATH; CELL INVASION; CELL KILLING; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOWN REGULATION; DRUG BIOAVAILABILITY; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; UPREGULATION;

EID: 84890399763     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.7235     Document Type: Article

References (48)

1. Subramaniam D, Ramalingam S, Houchen CW, Anant S. Cancer stem cells. A novel paradigm for cancer prevention and treatment. Mini Rev Med Chem 2010; 103:59-71.
2. Kawasaki BT, Hurt EM, Mistree T, Farrar WL. Targeting cancer stem cells with phytochemicals. Mol Interv 2008; 8:174-84.
3. Gullett NP, Ruhul Amin AR, Bayraktar S, et al. Cancer prevention with natural compounds. Semin Oncol 2010; 37:258-81.
4. Moiseeva EP, Manson MM. Dietary chemopreventive phytochemicals: Too little or too much? Cancer Prev Res (Phila) 2009; 2:611-6.
5. Mehta RG, Murillo G, Naithani R, Peng X. Cancer chemoprevention by natural products: How far have we come? Pharm Res 2010; 27:950-61.
6. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr 1995; 125:777S-83S.
7. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 1999; 129:1628-35.
8. Moiseeva EP, Almeida GM, Jones GD, Manson MM. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther 2007; 6:3071-9.
9. Rowe DL, Ozbay T, O'Regan RM, Nahta R. Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin. Breast Cancer 2009; 3:61-75.
10. Yodkeeree S, Ampasavate C, Sung B, Aggarwal BB, Limtrakul P. Demethoxycurcumin suppresses migration and invasion of MDA-MB-231 human breast cancer cell line. Eur J Pharmacol 2010; 627:8-15.
11. Hua WF, Fu YS, Liao YJ, et al. Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. Eur J Pharmacol 2010; 637:16-21.
12. Liu Q, Loo WT, Sze SC, Tong Y. Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFkappaB, cyclinD and MMP-1 transcription. Phytomedicine 2009; 16:916-22.
13. Kurahashi N, Iwasaki M, Sasazuki S, et al. Soy product and isoflavone consumption in relation to prostate cancer in japanese men. Cancer Epidemiol Biomarkers Prev 2007; 16:538-45.
14. Matsuo K, Hiraki A, Ito H, et al. Soy consumption reduces the risk of non-small-cell lung cancers with epidermal growth factor receptor mutations among japanese. Cancer Sci 2008; 99:1202-8.
15. Suzuki T, Matsuo K, Tsunoda N, et al. Effect of soybean on breast cancer according to receptor status: A case-control study in japan. Int J Cancer 2008; 123:1674-80.
16. Li Y, Ellis KL, Ali S, et al. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 2004; 28:e90-5.
17. Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG. Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 2006; 6:107.
18. Tonetti DA, Zhang Y, Zhao H, Lim SB, Constantinou AI. The effect of the phytoestrogens genistein, daidzein, and equol on the growth of tamoxifen- resistant T47D/PKC alpha. Nutr Cancer 2007; 58:222-9.
19. Acharya A, Das I, Singh S, Saha T. Chemopreventive properties of indole- 3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis. Recent Pat Food Nutr Agric 2010; 2:166-77.
20. Nguyen HH, Lavrenov SN, Sundar SN, et al. 1-benzyl-indole-3-carbinol is a novel indole-3-carbinol derivative with significantly enhanced potency of anti- proliferative and anti-estrogenic properties in human breast cancer cells. Chem Biol Interact 2010; 186:255-66.
21. Rahman KM, Sarkar FH, Banerjee S, et al. Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol Cancer Ther 2006; 5:2747-56.
22. Chen T, Wong YS, Zheng W. Induction of G1 cell cycle arrest and mitochondria- mediated apoptosis in MCF-7 human breast carcinoma cells by selenium- enriched spirulina extract. Biomed Pharmacother 2009; Epub.
23. Ismail MF, Ali DA, Fernando A, Abdraboh ME, Gaur RL, Ibrahim WM, Raj MH, Ouhtit A. Chemoprevention of rat liver toxicity and carcinogenesis by spirulina. Int J Biol Sci 2009; 5:377-87.
24. Hayashibara T, Yamada Y, Nakayama S, et al. Resveratrol induces downregulation in survivin expression and apoptosis in HTLV-1-infected cell lines: A prospective agent for adult T cell leukemia chemotherapy. Nutr Cancer 2002; 44:193-201.
25. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res 2004; 24:2783-840.
26. Harikumar KB, Kunnumakkara AB, Sethi G, et al. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 2010; 127:257-68.
27. Raj MH, Abd Elmageed ZY, Zhou J, et al. Synergistic action of dietary phyto- antioxidants on survival and proliferation of ovarian cancer cells. Gynecol Oncol 2008; 110:432-8.
28. Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett 2008; 269:315-25.
29. Duo J, Ying GG, Wang GW, Zhang L. Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation. Mol Med Rep. 2012; 5:1453-6.
30. Zhang H, Zhang M, Yu L, Zhao Y, He N, Yang X. Antitumor activities of quercetin and quercetin-5',8-disulfonate in human colon and breast cancer cell lines. Food Chem Toxicol. 2012; 50:1589-99.
31. Nebe B, Peters A, Duske K, Richter DU, Briese V. Influence of phytoestrogens on the proliferation and expression of adhesion receptors in human mammary epithelial cells in vitro. Eur J Cancer Prev 2006; 15:405-15.
32. Kim JH, Lee BK, Lee KW, Lee HJ. Resveratrol counteracts gallic acid-induced down-regulation of gap-junction intercellular communication. J Nutr Biochem 2009; 20:149-54.
33. Hill A, McFarlane S, Mulligan K, Gillespie H, Draffin JE, Trimble A, Ouhtit A, Johnston PG, Harkin DP, McCormick D, Waugh DJ. Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells. Oncogene 2006; 25:6079-91.
34. Leung TH, Ching YP, Yam JW, Wong CM, Yau TO, Jin DY, Ng IO. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci U S A 2005; 102:15207-12.
35. Scott EN, Gescher AJ, Steward WP, Brown K. Development of dietary phytochemical chemopreventive agents: Biomarkers and choice of dose for early clinical trials. Cancer Prev Res (Phila) 2009; 2:525-30.
36. Abdraboh ME, Gaur RL, Hollenbach AD, Sandquist D, Raj MH, Ouhtit A. Survivin is a novel target of CD44-promoted breast tumor invasion. Am J Pathol 2011, 179:555-63.
37. Ebina M, Martinez A, Birrer MJ, Ilona Linnoila R. In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers. Oncogene 2001; 20:2579-86.
38. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res 2002;4:70-6.
39. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2:a001107.
40. Riddle ND, Gorden L, Rojiani MV, Hakam A, Rojiani AM. CD44 and p53 immunoexpression patterns in NF1 neoplasms-indicators of malignancy and infiltration. Int J Clin Exp Pathol 2010; 3:515-21.
41. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011 Jan;223(2):116-26.
42. Xie Z, Chng WJ, Tay KG, Liu SC, Zhou J, Chen CS. Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers. Biotechnol Lett 2010. 33:221-8.
43. Nadkarni A, Rajesh P, Ruch RJ, Pittman DL. Cisplatin resistance conferred by the RAD51D (E233G) genetic variant is dependent upon p53 status in human breast carcinoma cell lines. Mol Carcinog 2009; 48:586-91.
44. Wang X, Wu X, Wang C, et al. Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-kappaB pathway in MCF-7 cells. FEBS Lett 2010;584:3392-7.
45. Kowalczyk MC, Kowalczyk P, Tolstykh O, Hanausek M, Walaszek Z, Slaga TJ. Synergistic effects of combined phytochemicals and skin cancer prevention in SENCAR mice. Cancer Prev Res (Phila) 2010;3:170-8.
46. Fan S, Meng Q, Auborn K, Carter T, Rosen EM. BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer 2006;94:407-26.
47. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea AD. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancr Ther 2006;5:952-61.
48. Papoutsis AJ, Lamore SD, Wondrak GT, Selmin OI, Romagnolo DF. Resveratrol prevents epigenetic silencing of BRCA1 by the aromatic hydrocarbon receptor in human breast cancer cells. J Nutr 2010;140:1607-14.